Stocks Tumbling on Lethargic Results: Colgate-Palmolive Company (NYSE:CL), Kimberly-Clark Corporation (NYSE:KMB)

Colgate-Palmolive Company (NYSE:CL) [Trend Analysis] knocking active thrust in leading trading session, shares a loss of -0.12% to 65.31 with around 3.81 Million shares have changed hands in this session. . The stock is going forward its fifty-two week low with 8.76% and lagging behind from its 52-week high price with -12.89%.

Similar, the positive performance for the quarter recorded as -9.05% and for the year was 5.36%, while the YTD performance remained at -0.20%. CL has Average True Range for 14 days of 0.77. In addition, the firm has price to earnings ratio of 42.74, which is authentic method to judge but not universal for all situation.

Fundament/ News Factor in Focus

Taking look on ratio analysis, CL has forward price to earnings ratio of 21.60, compare to its price to earnings ratio of 42.74. Adding one more ration to find detail valuation of security, price to earnings growth ration that stands at 5.06. The co is presenting price to cash flow as 39.20 and while calculating price to free cash flow it concluded at 57.05, the low single digit may indicate stock is undervalued and vice versa. On other hand, keeping in mind stable cash flows but few growth prospects make traders to value lower.

The firm has price volatility of 1.25% for a week and 1.11% for a month. Its beta stands at 0.71 times. Narrow down four to firm performance, its weekly performance was -1.43% and monthly performance was -1.48%.

Kimberly-Clark Corporation (NYSE:KMB) runs in leading trade, it inching up 0.04% to traded at $114.41. KMB attains analyst recommendation of 2.90 on scale of 1-5 with week’s performance of -0.67%.

To find out the technical position of KMB, it holds price to book ratio of 137.84 that unearth high-growth companies selling at low-growth prices, but it requires appropriate measurement approach. It has forward price to earnings ratio of 18.07, and price to earnings ratio calculated as 20.81. The price to earnings growth ration calculated as 2.74. KMB is presenting price to cash flow of 46.19 and free cash flow concluded as 46.13.

EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at -29.30%, and looking further price to next year’s EPS is 5.53%. While take a short look on price to sales ratio, that was 2.24 and price to earning ration of 20.81 attracting passive investors.

 

About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *